NEWS DETAIL

La FDA va examiner en priorité l’asciminib, un inhibiteur de STAMP de Novartis, pour le traitement de la leucémie myéloïde chronique – drugdiscoverytrends.com

FDA to prioritize review of Novartis STAMP inhibitor asciminib for chronic myeloid leukemia drugdiscoverytrends.com

Informations médicales July 21, 2026

该文章暂未提取到完整正文，已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。

المنتجات المرتبطة بهذا المقال

تمت مطابقة هذه المنتجات تلقائيا استنادا الى عنوان المقال وملخصه ومحتواه.

الاسئلة الشائعة

Which products are related to this article?

The system matched these relevant products from the article content: لوسيوس أسيميني – اشترِ عبر الإنترنت من Asciminib.

How can I view the medicines discussed in this article?

Use the related product cards below the article to review available specifications, prices, product information, and reviews.

Does this article replace advice from a doctor or pharmacist?

No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.